Eisai, Daiichi Sankyo Begin To Profit From 2008 Foreign M&As
This article was originally published in PharmAsia News
Executive Summary
Two Japanese drug makers that embarked on mergers and acquisitions abroad to offset loss of patent protection for key products are experiencing positive results